Insider filing · DXCM

Jacob Steven Leach bought $1.0M of DexCom (DXCM)

Executed Nov 10 2025, disclosed Nov 11 2025, the same day.

Over the 21 trading sessions from the disclosed entry session (Nov 10 2025), the stock returned +20.3% (delay-adjusted); from the execution session (Nov 10 2025), +20.3%. Derived: entry at the session's open, exit at the close 20 sessions later.

JL Jacob Steven Leach President & COO profile →

Jacob Steven Leach (President & COO) filed 1 Form 4 report in the trailing twelve months (1 purchase, 0 sales), most often in DexCom, Inc. (DXCM). Across 1 priced purchase filing, the average 21-session return was +20.3% from execution and +20.3% from disclosure (delay-adjusted; derived). The largest single filing was $1.0M of DXCM (18,200 sh across 2 lots, as filed), executed Nov 10 2025.

DXCM DexCom, Inc. DXCM · Healthcare · 49 filings in 24 months ticker →

Healthcare · DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) sy…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→